Уважаемые коллеги, доброго времени суток! Представляем вам ирландское научное издание Lung Cancer. Журнал имеет первый квартиль, издается в Elsevier Ireland Ltd., его SJR за 2022 г. равен 1,609, импакт-фактор 6,081, печатный ISSN - 0169-5002, электронный - 1872-8332, предметные области - Ингаляции и респираторная медицина, Онкология, Исследования рака. Вот так выглядит обложка:
Редактором является Рольф Штахел, контактные данные - rrespondence: Rolf.Stahel@etop-eu.org, lungcancer@elsevier.com.
Это международное издание, освещающее клинические, трансляционные и фундаментальные научные исследования злокачественных новообразований легких и грудной клетки. Приветствуются оригинальные исследовательские статьи, ранние отчеты, обзорные статьи, редакционные статьи и корреспонденция, охватывающие профилактику, эпидемиологию и этиологию, основы биологии, патологии, клиническую оценку, хирургию, химиотерапию, лучевую терапию, комбинированные методы лечения, а также другие методы лечения и исходы рака легких.
Адрес издания - https://www.sciencedirect.com/journal/lung-cancer
Пример статьи, название - Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. Заголовок (Abstract)
Objectives
Cisplatin plus irinotecan has been considered as the standard therapy in younger (<70 years old) patients for extensive-disease small-cell lung cancer (ED-SCLC) in Japan. However, there is a lack of high-quality evidence for the use of irinotecan in elderly patients with ED-SCLC. This study aimed to demonstrate that carboplatin plus irinotecan (CI) improves overall survival (OS) in elderly patients with ED-SCLC.
Materials and methods
This was a randomized Phase II/III trial which enrolled elderly patients with ED-SCLC. Patients were randomized to the CI or carboplatin plus etoposide (CE) arm in a 1:1 ratio. The CE group intravenously received carboplatin (AUC 5 mg/ml/min on day 1) and etoposide (80 mg/m2 on days 1–3) every 3 weeks for four cycles. The CI group received carboplatin (AUC 4 mg/ml/min on day 1) and irinotecan (50 mg/m2 on days 1 and 8) intravenously every 3 weeks for 4 cycles.
Results
In total, 258 patients were enrolled and randomized (CE arm, 129 patients; CI arm, 129 patients). The median overall survival, progression-free survival, and objective response rate of the CE vs. CI arms were 12.0 (95% CI, 9.3–13.7) vs. 13.2 (95% CI, 11.1–14.6) months (HR, 0.85 (95% CI, 0.65–1.11)) (one-sided P = 0.11), 4.4 (95% CI, 4.0–4.7) vs. 4.9 (95% CI, 4.5–5.2) months (HR, 0.85 (95% CI, 0.66–1.09)), and 59.5% vs. 63.2%, respectively. A higher incidence of myelosuppression was observed in the CE group, whereas a higher incidence of gastrointestinal toxicity was observed in the CI group. Three treatment-related deaths occurred (one due to lung infection in the CE arm, and one due to lung infection and sepsis each in the CI arm).
Conclusions
The CI treatment showed favorable efficacy; however, the difference was not statistically significant. These results suggest that CE should remain as the standard chemotherapy regimen for elderly patients with ED-SCLC.
Keywords: Extensive-disease small-cell lung cancer; Elderly patients; Carboplatin; Irinotecan; Etoposide; Randomized phase II/III trial